Maine et al., report post-hoc modeling of a secondary outcome of a Phase 1 clinical trial that assessed the long-term immunogenicity of a next-generation self-replicating RNA vaccine, RBI-4000 for rabies. The durability of immune responses from RBI-4000 is equal to or superior to a commercial vaccine using statistical decay modeling.
- Christian J. Maine
- Gaelle Picarda
- Parinaz Aliahmad
